📊 CRBU Key Takeaways
Is Caribou Biosciences, Inc. (CRBU) a Good Investment?
Caribou Biosciences is a pre-revenue clinical-stage biotech company with severe operating losses and massive cash burn that far exceeds revenue generation. With only $12.4M in cash against $111M annual operating cash burn, the company faces critical liquidity constraints and will require significant capital raises or major clinical success to avoid financial distress within 12 months.
Caribou Biosciences shows modest revenue growth, but its fundamentals remain dominated by extreme operating losses, deeply negative margins, and substantial cash burn. The balance sheet is helped by no long-term debt and strong near-term liquidity ratios, but the low cash balance relative to negative operating and free cash flow raises concern about funding durability and the quality of growth.
Why Buy Caribou Biosciences, Inc. Stock? CRBU Key Strengths
- Strong balance sheet with $122.2M stockholders equity provides substantial capital base
- Excellent liquidity position with 5.71x current ratio indicating near-term payment capability
- Zero long-term debt eliminates refinancing risk and interest burden
- Revenue growth of 11.7% YoY shows emerging commercial activity from R&D programs
- Debt-free capital structure reduces financial leverage risk
- Strong current and quick ratios indicate near-term balance sheet flexibility
- Revenue is growing year over year, showing some commercial or collaboration progress
CRBU Stock Risks: Caribou Biosciences, Inc. Investment Risks
- Catastrophic cash burn of $111M annually against only $12.4M cash reserves indicates 1.3 months of runway at current burn rate
- Operating losses of $148.3M on $11.2M revenue demonstrates completely unprofitable operations with losses 1,329% of revenue
- Pre-commercial biotech model creates absolute dependence on clinical trial success and future funding; single negative trial result could be fatal
- Negative free cash flow of $112.4M combined with minimal revenue makes the company entirely dependent on capital markets for survival
- High insider trading activity (14 Form 4 filings in 90 days) may indicate uncertainty or management exit timing concerns
- Operating and net margins are extremely negative, indicating an unsustainable cost structure
- Operating cash flow and free cash flow are deeply negative, implying continued cash burn
- Cash and equivalents appear low relative to annual losses, increasing financing risk if burn does not improve
Key Metrics to Watch
- Cash position and runway until next financing required
- Clinical trial progress and regulatory milestones for lead programs
- Monthly cash burn rate and achievement of operational cost reduction targets
- Ability to secure funding and terms of future capital raises
- Revenue growth trajectory from commercialization efforts
- Quarterly operating cash burn versus cash and equivalents
- Revenue growth relative to R&D and operating expense trends
Caribou Biosciences, Inc. (CRBU) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.71x current ratio provides a solid financial cushion.
CRBU Profit Margin, ROE & Profitability Analysis
CRBU vs Healthcare Sector: How Caribou Biosciences, Inc. Compares
How Caribou Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Caribou Biosciences, Inc. Stock Overvalued? CRBU Valuation Analysis 2026
Based on fundamental analysis, Caribou Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Caribou Biosciences, Inc. Balance Sheet: CRBU Debt, Cash & Liquidity
CRBU Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Caribou Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 10% decline. The most recent EPS of $-1.65 indicates the company is currently unprofitable.
CRBU Revenue Growth, EPS Growth & YoY Performance
CRBU Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.0M | -$27.5M | $-0.30 |
| Q2 2025 | $2.7M | -$37.7M | $-0.42 |
| Q1 2025 | $2.4M | -$40.0M | $-0.43 |
| Q3 2024 | $2.0M | -$10.0M | $-0.12 |
| Q2 2024 | $3.5M | -$28.0M | $-0.42 |
| Q1 2024 | $2.4M | -$28.0M | $-0.46 |
| Q3 2023 | $3.3M | -$10.0M | $-0.12 |
| Q2 2023 | $3.8M | -$19.1M | $-0.44 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Caribou Biosciences, Inc. Dividends, Buybacks & Capital Allocation
CRBU SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Caribou Biosciences, Inc. (CIK: 0001619856)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRBU
What is the AI rating for CRBU?
Caribou Biosciences, Inc. (CRBU) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRBU's key strengths?
Claude: Strong balance sheet with $122.2M stockholders equity provides substantial capital base. Excellent liquidity position with 5.71x current ratio indicating near-term payment capability. ChatGPT: Debt-free capital structure reduces financial leverage risk. Strong current and quick ratios indicate near-term balance sheet flexibility.
What are the risks of investing in CRBU?
Claude: Catastrophic cash burn of $111M annually against only $12.4M cash reserves indicates 1.3 months of runway at current burn rate. Operating losses of $148.3M on $11.2M revenue demonstrates completely unprofitable operations with losses 1,329% of revenue. ChatGPT: Operating and net margins are extremely negative, indicating an unsustainable cost structure. Operating cash flow and free cash flow are deeply negative, implying continued cash burn.
What is CRBU's revenue and growth?
Caribou Biosciences, Inc. reported revenue of $11.2M.
Does CRBU pay dividends?
Caribou Biosciences, Inc. does not currently pay dividends.
Where can I find CRBU SEC filings?
Official SEC filings for Caribou Biosciences, Inc. (CIK: 0001619856) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRBU's EPS?
Caribou Biosciences, Inc. has a diluted EPS of $-1.59.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CRBU a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Caribou Biosciences, Inc. has a SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CRBU stock overvalued or undervalued?
Valuation metrics for CRBU: ROE of -121.2% (sector avg: 15%), net margin of -1,327.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CRBU stock in 2026?
Our dual AI analysis gives Caribou Biosciences, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CRBU's free cash flow?
Caribou Biosciences, Inc.'s operating cash flow is $-111.0M, with capital expenditures of $1.4M. FCF margin is -1,006.8%.
How does CRBU compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,327.4% (avg: 12%), ROE -121.2% (avg: 15%), current ratio 5.71 (avg: 2).